ANI PHARMACEUTICALS, INC Cash and Cash Equivalents, Period Increase (Decrease)
ANI PHARMACEUTICALS, INC (ANIP) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$19.00 million for the 6-month period ending 2017-06-30, per its 10-Q filed 2017-08-03.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2017-08-03
- ANI PHARMACEUTICALS, INC cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was -$2.46M.
- ANI PHARMACEUTICALS, INC cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was -$16.54M.
- ANI PHARMACEUTICALS, INC cash and cash equivalents, period increase (decrease) for the quarter ending 2016-12-31 was $11.21M, a 197.27% increase year-over-year.
- ANI PHARMACEUTICALS, INC cash and cash equivalents, period increase (decrease) for the quarter ending 2016-09-30 was -$3.86M.
- ANI PHARMACEUTICALS, INC cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$127.32M.
- ANI PHARMACEUTICALS, INC cash and cash equivalents, period increase (decrease) for fiscal 2015 was -$14.35M, a 109.09% decline from fiscal 2014.
- ANI PHARMACEUTICALS, INC cash and cash equivalents, period increase (decrease) for fiscal 2014 was $157.93M, a 1323.58% increase from fiscal 2013.
- ANI PHARMACEUTICALS, INC cash and cash equivalents, period increase (decrease) for fiscal 2013 was $11.09M, a 100754.55% increase from fiscal 2012.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|---|---|
| 2017-06-30 | -$2.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | -$19.00M 10-Q · filed 2017-08-03 | -$7.79M derived: sum of 3 quarters · filed 2017-08-03 | -$11.65M derived: sum of 4 quarters · filed 2017-08-03 | ||
| 2017-03-31 | -$16.54M 10-Q · filed 2017-05-04 | -$5.33M derived: sum of 2 quarters · filed 2017-05-04 | -$9.19M derived: sum of 3 quarters · filed 2017-05-04 | -$66.92M derived: sum of 4 quarters · filed 2017-08-03 | ||
| 2016-12-31 | $11.21M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-02 | $7.35M derived: sum of 2 quarters · filed 2017-03-02 | -$50.38M derived: sum of 3 quarters · filed 2017-08-03 | -$127.32M 10-K · filed 2017-03-02 | ||
| 2016-09-30 | -$3.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | -$61.59M derived: sum of 2 quarters · filed 2017-08-03 | -$138.53M 10-Q · filed 2016-11-03 | -$134.76M derived: sum of 4 quarters · filed 2017-08-03 | ||
| 2016-06-30 | -$57.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | -$134.67M 10-Q · filed 2017-08-03 | -$139.67M 10-Q · filed 2016-08-04 | -$130.90M derived: sum of 3 quarters · filed 2017-08-03 | -$146.72M derived: sum of 4 quarters · filed 2017-08-03 | |
| 2016-03-31 | -$76.94M 10-Q · filed 2017-05-04 | -$73.17M derived: sum of 2 quarters · filed 2017-05-04 | -$88.98M derived: sum of 3 quarters · filed 2017-05-04 | -$87.82M derived: sum of 4 quarters · filed 2017-05-04 | ||
| 2015-12-31 | $3.77M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-02 | -$12.05M derived: sum of 2 quarters · filed 2017-03-02 | -$10.88M derived: sum of 3 quarters · filed 2017-03-02 | -$14.35M 10-K · filed 2017-03-02 | ||
| 2015-09-30 | -$15.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | -$14.65M derived: sum of 2 quarters · filed 2016-11-03 | -$18.12M 10-Q · filed 2016-11-03 | $115.86M derived: sum of 4 quarters · filed 2017-03-02 | ||
| 2015-06-30 | $1.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | -$2.31M 10-Q · filed 2016-08-04 | $131.68M derived: sum of 3 quarters · filed 2017-03-02 | $113.77M derived: sum of 4 quarters · filed 2017-03-02 | ||
| 2015-03-31 | -$3.47M 10-Q · filed 2016-05-05 | $130.51M derived: sum of 2 quarters · filed 2017-03-02 | $112.60M derived: sum of 3 quarters · filed 2017-03-02 | $114.19M derived: sum of 4 quarters · filed 2017-03-02 | ||
| 2014-12-31 | $133.99M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-02 | $116.08M derived: sum of 2 quarters · filed 2017-03-02 | $117.66M derived: sum of 3 quarters · filed 2017-03-02 | $157.93M 10-K · filed 2017-03-02 | ||
| 2014-09-30 | -$17.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-03 | -$16.32M derived: sum of 2 quarters · filed 2015-11-03 | $23.95M 10-Q · filed 2015-11-03 | $24.12M derived: sum of 4 quarters · filed 2016-02-23 | ||
| 2014-06-30 | $1.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | $41.86M 10-Q · filed 2015-08-04 | $42.03M derived: sum of 3 quarters · filed 2016-02-23 | $40.37M derived: sum of 4 quarters · filed 2016-02-23 | ||
| 2014-03-31 | $40.27M 10-Q · filed 2015-05-05 | $40.44M derived: sum of 2 quarters · filed 2016-02-23 | $38.78M derived: sum of 3 quarters · filed 2016-02-23 | $51.33M derived: sum of 4 quarters · filed 2016-02-23 | ||
| 2013-12-31 | $175.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-23 | -$1.49M derived: sum of 2 quarters · filed 2016-02-23 | $11.06M derived: sum of 3 quarters · filed 2016-02-23 | $11.09M 10-K · filed 2016-02-23 | ||
| 2013-09-30 | -$1.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $10.89M derived: sum of 2 quarters · filed 2014-11-10 | $10.92M 10-Q · filed 2014-11-10 | $10.92M 10-Q · filed 2013-11-07 | $10.78M derived: sum of 4 quarters · filed 2014-11-10 | |
| 2013-06-30 | $12.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $12.58M 10-Q · filed 2014-08-07 | $12.58M 10-Q · filed 2013-08-09 | $12.45M derived: sum of 3 quarters · filed 2014-08-07 | $12.48M derived: sum of 4 quarters · filed 2014-08-07 | |
| 2013-03-31 | $30.00K 10-Q · filed 2014-05-12 | -$107.33K derived: sum of 2 quarters · filed 2014-05-12 | -$78.62K derived: sum of 3 quarters · filed 2014-05-12 | |||
| 2012-12-31 | -$137.33K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28 | -$108.62K derived: sum of 2 quarters · filed 2014-02-28 | $11.00K 10-K · filed 2014-02-28 | |||
| 2012-09-30 | $28.71K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $148.33K 10-Q · filed 2013-11-07 | ||||
| 2012-06-30 | $119.62K 10-Q · filed 2013-08-09 | |||||
| 2011-09-30 | $32.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-09 | $31.44M 10-Q · filed 2011-11-09 | ||||
| 2011-06-30 | -$1.03M 10-Q · filed 2011-08-05 | |||||
| 2010-09-30 | -$10.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-09 | $5.67M 10-Q · filed 2011-11-09 | ||||
| 2010-06-30 | $16.52M 10-Q · filed 2011-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |